A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America

Bernard Rossi(Hospital Sírio-Libanês), Edenir Inêz Palmero(Hospital de Câncer de Barretos), Francisco López-Köstner(Clínica Las Condes), Carlos Sarroca(Hospital Central de las Fuerzas Armadas), Carlos Vaccaro(Hospital Italiano de Buenos Aires), Florencia Spirandelli(Hospital Provincial de Rosario), Patrícia Ashton‐Prolla(Universidade Federal do Rio Grande do Sul), Yenni Rodríguez(Clínica Santa María), Henrique de Campos Reis Galvão(Hospital de Câncer de Barretos), Rui Manuel Reis(University of Minho), André Escremim de Paula(Hospital de Câncer de Barretos), Luís Gustavo Capochin Romagnolo(Hospital de Câncer de Barretos), Karin Álvarez(Clínica Las Condes), Adriana Della Valle(Hospital Central de las Fuerzas Armadas), Florencia Neffa(Hospital Central de las Fuerzas Armadas), Pablo Kalfayan(Hospital Italiano de Buenos Aires), Enrique Spirandelli(Hospital Provincial de Rosario), Sergio Chialina(Hospital Provincial de Rosario), Melva Gutiérrez‐Angulo(Universidad de Guadalajara), María del Carmen Castro‐Mujica(Instituto Nacional de Enfermedades Neoplásicas), Julio Sanchez de Monte(Instituto Nacional de Cancerología), Richard Quispe, Sabrina Daniela da Silva(Jewish General Hospital), Norma Rossi(Hospital Privado), Claudia Barletta‐Carrillo(Instituto Nacional de Enfermedades Neoplásicas), Susana Revollo, Ximena Taborga, L. Lena Morillas, Hélène Tubeuf(Inserm), Érika Maria Monteiro Santos(Hospital Sírio-Libanês), Tamara Alejandra Piñero(Experimental Medicine and Biology Institute), Constantino Dominguez‐Barrera(National University of San Marcos), Patrik Wernhoff(Akershus University Hospital), Alexandra Martins(Inserm), Eivind Hovig(Oslo University Hospital), Pål Møller(Oslo University Hospital), Mev Dominguez–Valentin(Oslo University Hospital)
BMC Cancer
September 5, 2017
Cited by 51Open Access
Full Text

Abstract

BACKGROUND: Genetic counselling and testing for Lynch syndrome (LS) have recently been introduced in several Latin America countries. We aimed to characterize the clinical, molecular and mismatch repair (MMR) variants spectrum of patients with suspected LS in Latin America. METHODS: Eleven LS hereditary cancer registries and 34 published LS databases were used to identify unrelated families that fulfilled the Amsterdam II (AMSII) criteria and/or the Bethesda guidelines or suggestive of a dominant colorectal (CRC) inheritance syndrome. RESULTS: We performed a thorough investigation of 15 countries and identified 6 countries where germline genetic testing for LS is available and 3 countries where tumor testing is used in the LS diagnosis. The spectrum of pathogenic MMR variants included MLH1 up to 54%, MSH2 up to 43%, MSH6 up to 10%, PMS2 up to 3% and EPCAM up to 0.8%. The Latin America MMR spectrum is broad with a total of 220 different variants which 80% were private and 20% were recurrent. Frequent regions included exons 11 of MLH1 (15%), exon 3 and 7 of MSH2 (17 and 15%, respectively), exon 4 of MSH6 (65%), exons 11 and 13 of PMS2 (31% and 23%, respectively). Sixteen international founder variants in MLH1, MSH2 and MSH6 were identified and 41 (19%) variants have not previously been reported, thus representing novel genetic variants in the MMR genes. The AMSII criteria was the most used clinical criteria to identify pathogenic MMR carriers although microsatellite instability, immunohistochemistry and family history are still the primary methods in several countries where no genetic testing for LS is available yet. CONCLUSION: The Latin America LS pathogenic MMR variants spectrum included new variants, frequently altered genetic regions and potential founder effects, emphasizing the relevance implementing Lynch syndrome genetic testing and counseling in all of Latin America countries.


Related Papers

No related papers found

Powered by citation graph analysis